DRAX 5.0
Draxis Health, Inc., through its subsidiary, DRAXIS Specialty Pharmaceuticals, Inc., provides pharmaceutical products in the areas of sterile, including sterile lyophilized pharmaceuticals; nonsterile specialty pharmaceuticals; and radiopharmaceuticals. Its sterile products include liquid and freeze-dried injectables, and sterile ointments. The Company’s nonsterile products are produced as solid oral, liquid, and semi-solid dosage forms. Its radiopharmaceuticals are used for therapeutic and diagnostic molecular imaging applications. The company’s radiopharmaceutical products include BrachySeed, an Iodine-003125 brachytherapy implant, which is used for the treatment of various localized cancers; and MDP-25, a kit for the preparation of Technetium Tc99m Medronate Injection, which is used to demonstrate areas of altered osteogenesis or bone growth. In addition, it provides FIBRIMAGE, a proprietary targeted molecular imaging product to aid in the diagnosis of deep vein thrombosis, is in phase III clinical trial; and SOMATOSCAN, a preclinical stage product, which is used for imaging of neuroendocrine tumors, lymphoma, carcinoid, and small-cell lung cancer. The company has collaboration agreements with Pfizer for the development of Anipryl, which is a selegiline product for use in veterinary prescriptive applications; and GlaxoSmithKline Consumer Healthcare for the development of SpectroPhar line of dermatology products.
Thursday November 2, 6:30 am ET
Draxis Health Third Quarter on Track for Record Year
biz.yahoo.com
 |
